Position in LLY
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$560,133
-$862,751 QoQ
Shares Held
467
-69.8% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.15%
of 13F equity value
Holder Rank
#3,665
of 4,605 holders
Holding Since
Mar 2021
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Bridgefront Capital, LLC holds $6,932,010 across 7 Drug Manufacturers - General names. LLY ranks #4 (8.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
7,888 | $2,003,315 | |
| 2 | GILD |
Gilead Sciences, Inc.
|
15,448 | $1,951,700 | |
| 3 | PFE |
Pfizer Inc
|
59,596 | $1,435,071 | |
| 4 | LLY |
ELI LILLY & Co
This page
|
467 | $560,133 | |
| 5 | NVS |
Novartis AG
|
3,062 | $479,876 | |
| 6 | GSK |
GSK plc
|
6,458 | $338,528 | |
| 7 | OGN |
Organon & Co.
|
12,067 | $163,387 |
All Filings in LLY
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $560,133 | 467 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $1,422,884 | 1,547 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $710,363 | 661 | Shares | Sole | 2026-02-13 | |
| 2024-09-30 | $460,688 | 520 | Shares | Sole | 2024-11-14 | |
| 2024-03-31 | $219,384 | 282 | Shares | Sole | 2024-05-15 | |
| 2023-09-30 | $301,867 | 562 | Shares | Sole | 2023-11-14 | |
| 2022-09-30 | $200,800 | 621 | Shares | Sole | 2022-11-29 | |
| 2021-09-30 | $254,848 | 1,103 | Shares | Sole | 2021-11-12 | |
| 2021-06-30 | $492,320 | 2,145 | Shares | Sole | 2021-08-12 | |
| 2021-03-31 | $435,477 | 2,331 | Shares | Sole | 2021-05-17 | |
| No filing history on record for this holder in this stock. | ||||||